復星醫藥(02196.HK):首批臨床試驗受試者接種在研新型肺炎疫苗
內媒報道,復星醫藥(02196.HK)獲德國BioNTech授權的新型冠狀病毒mRNA疫苗(BNT162b1),第一期臨床試驗首批36位志願者已成功接種。負責臨床試驗的江蘇省疾控中心主任醫師李靖欣表示,是次臨床試驗招募志願者144名,觀察首批受試者後認為目前疫苗安全性良好,試驗觀察期將持續到12月。
於今年3月,復星醫藥獲德國BioNTech授權在中港澳台地區獨家開發、商業化基於其專有的mRNA技術平台研發、針對新型冠狀病毒的疫苗產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.